Companies › Olema Pharmaceuticals
2 active drug programs in 5 registered trials: 3 Phase 1, 2 Phase 3; Oncology; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Palazestrant (OP-1250) Complete Estrogen Receptor Antagonist | ESR1 | Phase 3 | Breast Cancer; Metastatic Breast Cancer | Dec 2027 |
| OP-3136 Selective inhibitor of KAT6A and KAT6B | KAT6A, KAT6B | Phase 1 | Advanced or Metastatic ER+ HER2- Breast Cancer (mBC) | May 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05266105 | Palazestrant (OP-1250) | Phase 1 | Breast Cancer | Oncology | Mar 2026 |
| NCT06784193 | OP-3136 | Phase 1 | Advanced or Metastatic ER+ HER2- Breast Cancer (mBC) | Oncology | May 2027 |
| NCT05508906 | Palazestrant (OP-1250) | Phase 1 | Metastatic Breast Cancer | Oncology | Dec 2027 |
| NCT06016738 | Palazestrant (OP-1250) | Phase 3 | Breast Cancer | Oncology | Feb 2028 |
| NCT07085767 | Palazestrant (OP-1250) | Phase 3 | Breast Cancer | Oncology | Dec 2028 |
Cash and short-term investments of $414m on 2026-09-30; operating cash outflow about $187m a year; runway about 27 months at that burn, to Dec 2028; 2 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 10 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Stemline Therapeutics ORIC Pharmaceuticals Shanghai Best-Link Bioscience ArriVent BioPharma Cogent Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.